Abstract
Current treatments for heart failure extend the life of the patient but do not stop the progression of the disease process. These treatments may not be addressing the underlying cause of cellular injury. The role of endothelin in cardiac remodeling and inflammation may be important in the progression of failure, and endothelin antagonists may be beneficial in treatment in combination with drugs already in use.